Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...364365366367368369370371372373374...401402»
  • ||||||||||  The Ratio Serum Creatinine/Serum Cystatin C as a Predictor of Ischemic Risk in Elderly Patients With Coronary Artery Disease () -  Oct 1, 2019 - Abstract #TCT2019TCT_446;    
    A Cox proportional hazard model showed that a lower serum creatinine/serum cystatin C ratio is an independent predictors of MACE events in elderly patients with coronary artery disease at 3 years (hazard ratio: 2.18; 95% confidence interval: 1.57 to 3.03; p < .001). Conclusion Serum creatinine/serum cystatin C ratio is a predictor of ischemic events in elderly patients with coronary artery disease but not for bleeding events.
  • ||||||||||  A UNIQUE TRANSCRIPTOME AND TRANSLATOME PATTERN DURING HYPERAMMONEMIA IN SARCOPENIA OF CIRRHOSIS. (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_3018;    
    The distinct patterns on transcripts and proteome reflect the effects of hyperammonemia and may be due to translational defects during hyperammonemia due to perturbations in initiation factor and mitochondrial components. Therapies targeting mitochondria and ribosomes have potential to reverse sarcopenia in cirrhosis.
  • ||||||||||  ADIPOSE TISSUE DISTRIBUTION IN RELATION TO INSULIN RESISTANCE IN PATIENTS WITH CIRRHOSIS (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_2971;    
    Higher SAT was beneficial for survival in patients with abnormal glucose tolerance, particularly in compensated cirrhosis. Sarcopenia and VAT, however, were not associated with mortality in cirrhotic patients with abnormal glucose tolerance.
  • ||||||||||  chloroquine phosphate / Generic Mfg.
    ANAPLEROTIC FATTY ACID DOES NOT REVERSE AMMONIA INDUCED SKELETAL MUSCLE SIGNALING OR METABOLIC PERTURBATIONS (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_2914;    
    Hyperammonemia impaired protein synthesis in myotubes and TCA cycle intermediate concentrations and resulted in a sarcopenic phenotype. There perturbations were not reversed by supplementation with a synthetic fatty acid, DODA, with anaplerotic potential suggesting that fatty acid supplementation may not be beneficial in reversing the sarcopenia in cirrhosis.
  • ||||||||||  prednisone / generics
    DYNAMIC IMPROVEMENT IN VISCERAL ADIPOSE REDISTRIBUTION FOLLOWING LIVER TRANSPLANTATION (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_2465;    
    Unlike SM and BMI, VSR is very dynamic in the first 1-2 years post-LT with improvement in most but not all LT recipients. Future studies are needed to determine whether improvement in visceral adiposity post-LT reduces the risk for metabolic syndrome and associated complications.
  • ||||||||||  IMPAIRED mTORC1 SIGNALING DURING HYPERAMMONEMIA IN CIRRHOSISIS PARTIALLY REVERSED BY DELETION OF GCN2. (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_1935;    
    We demonstrate a novel IRE1α/XBP1 mediated N-glycosylation in the skeletal muscle during hyperammonemia that contributes to increased autophagy and loss of muscle mass. During hyperammonemia, GCN2 is a critical mediator of hyperammonemia-induced dysregulated proteostasis and consequent sarcopenia via regulation of translation initiation and mitochondrial function and is a potential molecular target to restore muscle mass in patients with cirrhosis.
  • ||||||||||  METABOLIC ALTERATIONS IN ADULTS WITH HOMOZYGOUS alpha1-ANTITRYPSIN DEFICIENCY (PI*ZZ GENOTYPE) (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_1656;    
    During hyperammonemia, GCN2 is a critical mediator of hyperammonemia-induced dysregulated proteostasis and consequent sarcopenia via regulation of translation initiation and mitochondrial function and is a potential molecular target to restore muscle mass in patients with cirrhosis. Our data demonstrate that even otherwise healthy Pi*ZZ individuals already display insulin resistance as well as alterations in lipid metabolism, that warrant further exploration.
  • ||||||||||  ON THE DEFINITION OF SARCOPENIA WITHIN NAFLD – RESULTS FROM THE LARGE UK BIOBANK IMAGING STUDY (Sheraton Boston Hotel, Constitution Ballroom) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_1467;    
    FFMViVCG enables BMI invariant sarcopenia detection, opening up the possibility to address sarcopenia in NAFLD. In addition, VCG adjustment strengthened the link between FFMV and hospital nights/functional outcomes, indicating higher clinical relevance of assessing the deviation from expected muscle volume.
  • ||||||||||  PREVALENCE AND OUTCOMES OF SARCOPENIA IN PEDIATRIC LIVER TRANSPLANTATION (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_1252;    
    Sarcopenia is prevalent in 42.3% of a pediatric population undergoing LT and is associated with longer duration of ICU stay in this pilot study. Multi-center studies are needed to further explore long and short term effects of sarcopenia post pediatric LT.
  • ||||||||||  SARCO-MODEL, A NOVEL SCORE TO BETTER PREDICT THE RISK OF DEATH IN CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_1072;    
    Sarco-Model should represent a useful predictor of mortality, mainly in enlisted patients in which the mortality risk is underestimated by MELD (i.e., severe ascites). Sarco-Model can identify the “high-risk” patients not conventionally captured by the MELD determinants, therefore being a useful tool for reducing the waiting list mortality and for improving the allocation process.
  • ||||||||||  SARCOPENIA AS A PROGNOSTIC FACTOR IN CIRRHOSIS (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_1071;    
    Sarcopenia in Child A patients was predominantly seen in NASH related cirrhosis. Sarcopenia significantly correlated with six month mortality, number of decompensations, frequency of hospitilisations, CHILD and MELD scores.
  • ||||||||||  SARCOPENIA IS ASSOCIATED WITH LIVER DISEASE SEVERITY IN PEDIATRIC NAFLD (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_1069;    
    Sarcopenia HIBA score is an easy, reliable and objetive tool with an excellent diagnosis capability, which may help to choose properly the patients who require to be evaluated for the presence of sarcopenia by SMI. Muscle mass was associated with severity of NAS in a pediatric cohort with histologically confirmed NAFLD, as well as with MRI fat fraction in a cohort with MRI evidence of hepatic steatosis.
  • ||||||||||  SIGNIFICANT IMPROVEMENT IN MARKERS OF FRAILTY FOLLOWING TWELVE WEEKS OF AEROBIC EXERCISE IN INDIVIDUALS WITH NAFLD (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_1011;    
    That the benefits were not maintained at T2 indicates a need for strategies to integrate exercise and physical activity into a community-based setting to promote long term robustness. Frailty has been shown to greatly increase physician/hospital visits and exercise therapy may represent a therapeutic target to manage this challenging feature of NAFLD.
  • ||||||||||  Clinical, Journal:  Physical Activity in Liver Transplantation: A Patient's and Physicians' Experience. (Pubmed Central) -  Sep 28, 2019   
    However, the importance of regular, individualized and patient-adapted physical activity is still understudied and underestimated. This article describes a three-sided perspective on the importance of physical activity in the setting of liver transplantation, including a patient's, transplant surgeon's and hepatologist's point of view.
  • ||||||||||  Clinical, Review, Journal:  Glucose metabolism in older patients (Pubmed Central) -  Sep 28, 2019   
    We review the role of increasing insulin resistance, age-related β‑cell dysfunction and incretin secretion. The clinical relevance of these effects will also be discussed in regard to the central geriatric syndrome of sarcopenia and antidiabetic drug therapy.